Gyre Therapeutics, Inc. GYRE

Updated: 9 Aug 2026

NASDAQ | Biotech | Biotechnology and pharmaceuticals

No signal published yet

We already track Gyre Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Gyre Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and pharmaceuticals
We're already tracking Gyre Therapeutics, Inc. — here are the latest events we've registered

Recent News

  • On August 7, 2026, Gyre Therapeutics reported second-quarter 2026 financial results with $29.1 million in revenue and affirmed its full-year 2026 revenue guidance. The company highlighted commercial progress in China, regulatory updates on its New Drug Application for F351 in liver fibrosis, and the completion of its Cullgen acquisition.

What Firelda Watch includes for Gyre Therapeutics, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Gyre Therapeutics, Inc. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Recipharm
RECI B
NEUTRAL
Viatris Inc.
VTRS
HOLD
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL

Biotech

More companies in this sector

Want to follow Gyre Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Gyre Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Gyre Therapeutics, Inc. GYRE
Gyre Therapeutics — follow and we'll monitor it
Follow Gyre Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.